Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Distribution, selling, general and administrative expenses

Restructuring and employee severance

Amortization and other acquisition-related costs

Impairments and (gain)/loss on disposal of assets, net

Litigation (recoveries)/charges, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Cardinal Health

Cordis develops and manufactures medical devices for diagnostics and interventional procedures to treat patients suffering from coronary and peripheral vascular diseases.On October 4, 2015, Cardinal Health announced that it has completed the acquisition of Johnson & Johnson's Cordis business for $1.944 billion.

Cordis

Cardinal Health, Inc. is a healthcare services and products company, which engages in the provision of customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. It also provides medical products and pharmaceuticals and cost-effective solutions that enhance supply chain efficiency. The firm operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical and over-the-counter healthcare and consumer products. The Medical segment manufactures, sources and distributes Cardinal Health branded medical, surgical, and laboratory products. The company was founded by Robert D. Walter in 1979 and is headquartered in Dublin, OH.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Cardinal Health reports strong Q3 results, focuses on Pharma growth

Cardinal Health's Q3 results demonstrated strong performance in the Pharma segment, while the Medical segment faced challenges. The company raised its guidance for the year and emphasized the importance of Red Oak Sourcing in maintaining market dynamics. Looking ahead, the company is focused on executing its medical improvement plan and maximizing shareholder value.

Cardinal Health reports stable Q2 growth, eyes Pharma segment

Cardinal Health's Q2 2023 performance showcased stability and growth in the Pharma segment, with a return to profitability in the Medical segment.
The company's strategic focus on executing key priorities and driving shareholder value creation is evident in its financial results.
Challenges such as international freight costs and supply chain headwinds are being addressed, while opportunities in COVID therapies, pricing strategy, and growth investments are being pursued.
Overall, Cardinal Health's revised outlook and strong performance in key segments position it for continued growth and financial success.

Cardinal Health reports robust Q3 earnings, eyes biosimilars for growth

Cardinal Health delivered strong financial performance in Q3 2023, driven by robust growth in the Pharma segment.
While facing challenges in the Medical segment, the company remains focused on mitigating inflation and maximizing shareholder value.
With a positive outlook on future growth opportunities, Cardinal Health aims to address cost pressures and drive profitability.

Cardinal Health achieves record results, raises guidance for fiscal '24

Cardinal Health's strong performance in Q4 and fiscal year 2023, coupled with strategic initiatives and guidance raise, position the company for continued growth and success.
Challenges such as inflation mitigation and cost pressures are being addressed, while opportunities in organic growth and strategic investments pave the way for future profitability.
The company's focus on advancing Pharma, executing the Medical Improvement Plan, and maximizing shareholder value creation underscores its commitment to sustained growth and value creation.

Cardinal Health reports strong Q1 earnings, raises guidance for FY24

Cardinal Health's Q1 2024 earnings call showcased robust performance, with profit growth in both Pharma and Medical segments. The company raised EPS guidance, demonstrated strong cash flow generation, and emphasized customer service and shareholder value creation. Challenges include managing margins, nonoperating items, and commodity price impacts, while opportunities lie in healthcare sector growth, innovation, and market dynamics.

Cardinal Health reports robust Q2 earnings, raises EPS guidance

Cardinal Health's Q2 performance reflects strong revenue growth, improved cash flow, and raised EPS guidance, supported by strategic acquisitions and growth initiatives.
While facing challenges from nonrecurring adjustments and SG&A growth, the company remains focused on core businesses and driving future growth opportunities.
With a positive outlook on market-driven growth, cost management, and strategic priorities, Cardinal Health aims to sustain its momentum and deliver value to shareholders.

Cardinal Health reports robust Q3 earnings, eyes growth opportunities ahead

Cardinal Health's Q3 performance reflects strong financial results and strategic progress across key segments, with raised guidance for fiscal '24 and '25.
The company faces challenges such as managing customer transitions and inflationary impacts but is well-positioned to capitalize on growth opportunities.
By focusing on cost optimization, strategic partnerships, and customer-centric solutions, Cardinal Health aims to drive sustained growth and profitability.
Investments in technology, brand growth, and operational efficiency underscore Cardinal Health's commitment to delivering value to shareholders and customers.

Cardinal Health excels in fiscal '24, raises guidance for '25

Cardinal Health's strong performance in fiscal year '24, highlighted by record financial results and strategic progress, positions the company for continued success.
Despite challenges such as market dynamics and customer transitions, the company's raised guidance for fiscal year '25 underscores confidence in future growth.
By capitalizing on strengths like revenue growth in key segments and making strategic investments, Cardinal Health is poised to navigate challenges and seize opportunities for sustained growth.

Cardinal Health reports strong Q1 performance and raises fiscal guidance

Cardinal Health's Q1 performance showed strength in Pharma and Specialty Solutions despite revenue decrease.
Challenges in GMPD segment and nuclear supply disruptions are being addressed for minimal impact.
Opportunities lie in continued cost reductions, growth normalization, and operational improvements.
Overall, Cardinal Health is well-positioned to navigate challenges and capitalize on growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

First Bancorp

Fulton Financial

Genuine Parts

GlaxoSmithKline

Huntington Bancshares

Haleon PLC

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Paramount Global

Philip Morris

Schlumberger

TotalEnergies SE

Our total dividend income decreased from $771.96 received in July 2021. Canadian Imperial takes the crown for the largest dividend payment of the month.

Bert's July Dividend Income Summary | Dividend Investing 2022

Cardinal Health, Inc. (NYSE:CAH ) Q4 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Kevin Moran - VP, IR Michael Kaufmann - CEO & Director Jason Hollar - CFO Conference Call Participants Lisa Gill - JPMorgan Chase & Co. George Hill - Deutsche Bank Michael Cherny - Bank of America Merrill Lynch Steven Valiquette - Barclays Bank Eric Percher - Nephron Research Charles Rhyee - Cowen and Company Rivka Goldwasser - Morgan Stanley Kevin Caliendo - UBS Elizabeth Anderson - Evercore ISI Operator Good day, and welcome to the Fourth Quarter and Full Year 2022 Cardinal Health Inc. Earnings Conference Call. Today's conference is being recorded.

Cardinal Health, Inc. (CAH) CEO Michael Kaufmann on Q4 2022 Results - Earnings Call Transcript

Cardinal Health's (CAH) fiscal fourth-quarter results benefit from a solid performance in the Pharmaceutical segment.

Cardinal Health (CAH) Q4 Earnings Lag Estimates, Revenues Top

Cardinal (CAH) delivered earnings and revenue surprises of -10.26% and 5.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardinal Health (CAH) Lags Q4 Earnings Estimates

Cardinal Health Inc. shares CAH, +1.59% slumped 4.5% in premarket trade Thursday, after the drug distributor missed profit estimates for the second quarte and announced a leadership change. The company posted net income of $138 million, or 50 cent a share, for the quarter, up from $116 million, or 40 cents a share, in the year-earlier period.

Cardinal Health shares slump premarket after profit miss, CEO change

Revenue increased 11% to $47.1 billion in the fourth quarter GAAP 1 operating earnings were $36 million in the fourth quarter; GAAP diluted EPS were $0.50 in the fourth quarter Non-GAAP operating earnings increased 41% to $450 million in the fourth quarter; non-GAAP diluted EPS increased 36% to $1.05 in the fourth quarter Generated operating cash flow of $3.1 billion in fiscal year 2022 Company provides fiscal year 2023 guidance and reiterates long-term targets Company introduces Medical Improvement Plan, targeting Medical segment profit of at least $650 million by fiscal year 2025 DUBLIN, Ohio , Aug. 11, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported fourth quarter fiscal year 2022 revenues of $47.1 billion, an increase of 11% from the fourth quarter of last year. GAAP operating earnings were $36 million, primarily due to a non-cash, pre-tax goodwill impairment charge of $303 million in the Medical segment.

Cardinal Health Reports Fourth Quarter and Full Year Results for Fiscal Year 2022

-- Mike Kaufmann to Step Down as Chief Executive Officer and from Board of Directors -- -- Jason Hollar, Chief Financial Officer, Named Chief Executive Officer -- -- Patricia English to Serve as Interim Chief Financial Officer -- DUBLIN, Ohio , Aug. 11, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors has elected Jason Hollar as the company's next Chief Executive Officer, effective September 1, 2022.  Hollar will also join the Board of Directors effective August 11, 2022.

Cardinal Health Announces Leadership Changes

Cardinal Health's (CAH) fiscal fourth-quarter results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.

Cardinal Health (CAH) to Post Q4 Earnings: What's in Store?

Greene previously served as SVP of EIT for the company's Pharmaceutical Segment DUBLIN, Ohio , Aug. 1, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that Michelle Greene has been named chief information officer. Greene will report to CEO, Mike Kaufmann and join the company's executive committee.

Cardinal Health Names Michelle Greene as Chief Information Officer

TO:       ALL PERSONS AND ENTITIES THAT HELD CARDINAL HEALTH, INC. COMMON STOCK AS OF THE CLOSE OF TRADING ON MAY 25, 2022 AND THAT CONTINUE TO HOLD CARDINAL HEALTH COMMON STOCK AS OF THE CLOSE OF TRADING ON OCTOBER 4, 2022.

Summary Notice to Stockholders of Cardinal Health, Inc. of Proposed Settlement of Stockholder Derivative Action, Settlement Hearing, and Right to Appear

AbbVie

Con Ed

V.F.

Exxon Mobil

The stock market is off to the worst start in almost 100 years, and things likely will get worse before they get better.

The 7 Highest-Yielding Dividend Aristocrats You Can Buy Now and Hold Forever

Cardinal Health's (CAH) latest acquisition is expected to significantly improve patients' health outcomes with improved medication adherence and increased satisfaction.

Cardinal Health's (CAH) New Buyout to Boost Medication Adherence

Cardinal Health's (CAH) latest acquisition is expected to significantly boost its distribution opportunities and improve patient service.

Cardinal Health (CAH) Buys Bendcare CPO-GPO, Invests in Its MSO

DUBLIN, Ohio , July 7, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release fourth-quarter and year-end financial results for its fiscal year 2022 on August 11, prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m.

Cardinal Health to Announce Fourth-Quarter and Year-End Results for Fiscal Year 2022 on August 11

Strengthening Cornerstone Rheumatology™ GPO as a leading rheumatology-focused GPO by providing innovative solutions and robust specialty drug access to over 1,300 rheumatology providers nationwide.   DUBLIN, Ohio , July 6, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has acquired the Bendcare group purchasing organization (CPO-GPO) entity and made a minority investment in the Bendcare management services organization (MSO).

Cardinal Health acquires the Bendcare CPO-GPO entity and makes a minority investment in the Bendcare MSO

Aflac

Essex Property Trust

General Dynamics

Walmart

The second-quarter gross domestic product (GDP) is likely to end up being negative, as the latest data from the Atlanta Fed's GDPNow tracker predicts real GDP growth of −1.0% as of June 30, down from +0.3% on June 27.

We Are in a Recession: 7 Dividend Aristocrats Are the Best Second-Half Ideas

Amazon

Salesforce

Lam Research

Palo Alto Networks

Sometimes you just have to hold your nose and dive in, knowing that the near future may still dish out unnerving volatility.

5 High-Conviction Stocks to Buy in This Market Correction

Cardinal Health's (CAH) latest collaboration is expected to significantly boost its distribution strategy and improve patient service.

Cardinal Health (CAH) Ties Up to Deliver Products Via Drones

DUBLIN, Ohio , June 29, 2022 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced the launch of an inventory reserve program that helps labs and health systems more accurately pre-order respiratory diagnostics before the onset of seasonal flu, strep and RSV. This new program provides clearer demand signals to the supply chain ahead of the season, which helps reduce the friction felt across the healthcare landscape as the season ramps.

Cardinal Health Inventory Program Helps Reduce Delays and Shortages Ahead of Respiratory Season

Alibaba

Cleveland-Cliffs

Etsy

Exelon

Fiserv

Pinterest

These oversold stocks are trading at multi-year lows and offer tremendous long-term growth potential to investors looking for bargains. The post 7 Oversold Stocks to Buy After the Market Crash appeared first on InvestorPlace.

7 Oversold Stocks to Buy After the Market Crash

Acme United

Algonquin Power & Utilities

Alexandria Real Estate Equities

Bank of Nova Scotia

CVB Financial

Investar Hhld

Lennox International

National Fuel Gas

National HealthCare

TowneBank

W. P. Carey

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. They have an average increase of 5.4% and a median increase of 4.4%. I've tracked 313 increases in 2022, 211 increases in Q1 2022, and 107 in Q2.

13 Upcoming Dividend Increases Including One King

Alnylam Pharmaceuticals

Baxter

Biogen

Boston Scientific

Gilead Sciences

Johnson & Johnson

If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.

Seven reasons the beleaguered biotech sector is now a ‘buy'

News for Cardinal Health Stock (CAH)